Table 2 Clinical trials related to the combination therapy of PARP inhibitors
Trail ID | Therapeutic Drugs | Phase | Status | Cancer type | Primary outcomes |
|---|---|---|---|---|---|
NCT04669002 | EP0057 Olaparib tablets | II | Recruiting | Ovarian Cancer | Overall Response Rate |
NCT01623349 | BKM120 and Olaparib BYL719 and Olaparib | I | Completed | Ovarian Cancer breast cancer | Maximum tolerated dose Recommended Phase 2 dose |
NCT03462342 | Olaparib Pill AZD6738 | II | Recruiting | High Grade Serous Carcinoma | Incidence of treatment-emergent adverse events Response rate |
NCT05494580 | Pamiparib Surufatinib | I and II | Not yet recruiting | Ovarian Cancer Ovarian Carcinoma Platinum-resistant Ovarian Cancer Fallopian Tube Carcinosarcoma Primary Peritoneal Cancer | Maximum tolerated dose Recommended Phase 2 dose Response Rate |
NCT05071937 | ZEN003694 Talazoparib | II | Recruiting | Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer | Objective Response |
NCT04267939 | Elimusertib (BAY1895344) Niraparib | I | Recruiting | Advanced Solid Tumors (Excluding Prostate Cancer) Ovarian Cancer | Maximum tolerated dose Recommended Phase 2 dose |
NCT04566952 | Anlotinib Olaparib | II | Recruiting | Ovarian Cancer Ovarian and Fallopian Tube Cysts and Neoplasms Neoplasms by Site Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Carcinoma, Ovarian Epithelial Ovarian Diseases Adnexal Diseases Genital Diseases, Female Carcinoma Anlotinib PARP Inhibitors BRCA1 Mutation Angiogenesis Antineoplastic Agents BRCA2 Mutation | Progression Free Survival Adverse events |
NCT02681237 | Cediranib Olaparib | Not Applicable | Completed | Ovarian Cancer | Objective Response Rate Progression-Free Survival Rate |
NCT05295589 | Copanlisib Hydrochloride Olaparib Paclitaxel Pegylated Liposomal Doxorubicin Hydrochloride Topotecan Hydrochloride | II | Recruiting | Platinum-Refractory Fallopian Tube Carcinoma Platinum-Refractory Ovarian Carcinoma Platinum-Refractory Primary Peritoneal Carcinoma Recurrent Fallopian Tube Endometrioid Adenocarcinoma Recurrent Fallopian Tube High Grade Serous Adenocarcinoma Recurrent Ovarian Endometrioid Adenocarcinoma Recurrent Ovarian High Grade Serous Adenocarcinoma Recurrent Platinum-Resistant Fallopian Tube Carcinoma Recurrent Platinum-Resistant Ovarian Carcinoma Recurrent Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Primary Peritoneal Endometrioid Adenocarcinoma Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma | Progression free survival |
NCT02571725 | Olaparib Tremelimumab | I and II | Active, not recruiting | Ovarian Cancer Fallopian Tube Cancer Peritoneal Neoplasms | Recommended Phase 2 Dose Objective response rate |
NCT05327010 | BET Bromodomain Inhibitor ZEN-3694 Talazoparib | II | Recruiting | Advanced Malignant Solid Neoplasm Advanced Ovarian Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Ovarian Carcinoma Recurrent Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Stage III Ovarian Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 | Objective response rate |
NCT04149145 | M4344 + Niraparib | I | Not yet recruiting | Ovarian Cancer Recurrent | Percentage of patients with treatment emergent adverse events Maximum tolerated dose |
NCT02446600 | Carboplatin Cediranib Maleate Gemcitabine Gemcitabine Hydrochloride Olaparib Paclitaxel Pegylated Liposomal Doxorubicin Hydrochloride | III | Active, not recruiting | Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Tumor Ovarian Seromucinous Carcinoma Ovarian Serous Tumor Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Endometrioid Adenocarcinoma Recurrent Primary Peritoneal Carcinoma | Progression free survival |
NCT03330405 | Avelumab Phase 1b Talazoparib Phase 1b Avelumab Phase 2 Talazoparib Phase 2 | II | Active, not recruiting | Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors | Dose Limiting Toxicity Overall Response |
NCT02484404 | Olaparib Cediranib Durvalumab | I and II | Recruiting | Colorectal Neoplasms Breast Neoplasms | Overall response rate Recommended phase II dose |